PDF(Pubmed)
Abstract：
Pulmonary mucinous adenocarcinoma (PMA), a distinct subtype of non-small cell lung cancer (NSCLC), is characterized by an abundance of mucin-producing cells. Although this subtype comprises a relatively small fraction of lung adenocarcinomas, PMA stands apart due to its unique clinical, pathological, and molecular features. This review comprehensively discusses the pathophysiology and etiology, clinical features, diagnostic methods, treatment strategies, prognosis, and future directions for PMA, drawing from relevant literature and existing studies. Advances in PMA treatment includes surgical intervention, targeted therapy, immunotherapy, and adjuvant therapy. Particularly, we discussed factors influencing the prognosis of PMAs, such as molecular markers, pathological features, and the impact of the latest treatment advances on prognosis. Moreover, we intended this review to be a comprehensive reference for diagnosing, treating, and assessing the prognosis of PMA, providing valuable guidance for clinical practice.
摘要：
肺黏液腺癌(PMA),非小细胞肺癌（NSCLC）的不同亚型，其特征是大量的产粘蛋白细胞。尽管该亚型包含相对较小比例的肺腺癌，PMA由于其独特的临床而与众不同，病态,和分子特征。这篇综述全面讨论了病理生理学和病因学，临床特征,诊断方法,治疗策略,预后,以及PMA的未来方向，借鉴相关文献和现有研究。PMA治疗的进展包括手术干预，靶向治疗,免疫疗法，和辅助治疗。特别是,我们讨论了影响PMAs预后的因素，如分子标记，病理特征,以及最新治疗进展对预后的影响。此外，我们希望这次审查是诊断的全面参考，治疗,并评估PMA的预后，为临床实践提供有价值的指导。
